文献速递炎症性肠病消化道肿瘤与早癌

硫唑嘌呤类药物与炎症性肠病患者及无炎症性肠病对照个体的癌症风险:丹麦全国队列研究(1996-2018)

Thiopurines and the Risk of Cancer in Patients With Inflammatory Bowel Disease and Reference Individuals Without Inflammatory Bowel Disease: A Danish Nationwide Cohort Study (1996-2018).
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-28

该丹麦全国队列研究纳入1996至2018年确诊的43419例炎症性肠病(IBD)患者,随访中位8.2年,评估硫唑嘌呤类药物暴露与癌症风险的关系。结果显示IBD患者各年龄段癌症风险均高于无IBD个体,单药及联合治疗均增加癌症风险,联合治疗在>65岁患者中aHR达2.79,停药后风险回落至未暴露水平。

要点

  • IBD患者各年龄段癌症风险均高于无IBD个体,<50岁aHR 1.59。
  • 硫唑嘌呤单药aHR 1.36,联合治疗aHR 2.49,均较未暴露者升高。
  • >65岁联合治疗者aHR 2.79,累计暴露>5年者aHR 1.36,停药后aHR 0.89回落至未暴露水平。

核心结论

  • 硫唑嘌呤类药物与癌症风险升高相关,尤其在老年患者联合治疗时更为明显;暴露超过5年风险增加36%;停药后风险回落至基线水平。

研究设计与样本

  • 丹麦全国登记队列研究,纳入1996至2018年确诊的43419例IBD患者,随访中位8.2年(四分位距3.7-14.2年),采用Cox回归比较IBD与非IBD个体的癌症风险,并评估IBD患者累积药物暴露与首次癌症(排除非黑色素瘤皮肤癌)的关联。

主要发现

  • IBD患者中报告癌症3128例(7.2%)。
  • 与无IBD个体相比,IBD患者各年龄段癌症风险均升高:<50岁aHR 1.59(95%CI 1.43-1.77),50-65岁aHR 1.31(95%CI 1.19-1.44),>65岁aHR 1.14(95%CI 1.05-1.24)。
  • 与未暴露的IBD患者相比,单药治疗aHR 1.36(95%CI 1.17-1.57),联合治疗aHR 2.49(95%CI 1.64-3.78)。
  • >65岁患者中,联合治疗者aHR 2.79(95%CI 1.24-6.28)。
  • 停药患者aHR回落至未暴露水平(aHR 0.89,95%CI 0.78-1.01);累积暴露>5年者aHR 1.36(95%CI 1.15-1.61)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Thiopurine therapy is a cornerstone in the treatment of inflammatory bowel disease (IBD). We aimed to assess the effect of thiopurines on cancer risk in IBD according to drug exposure and age. METHODS: Danish national registers were used to identify incident IBD patients, exposure to drugs, and status of cancers, in 1996 to 2018. Cox regressions were used to compare cancer risks in IBD and non-IBD individuals and to assess IBD patients' cumulative drug exposure and the association to first cancer, excluding non-melanoma skin cancer. RESULTS: We followed 43,419 patients with IBD for a median of 8.2 years (interquartile range, 3.7-14.2 years) after IBD diagnosis. Cancer was reported in 3128 (7.2%) patients with IBD. The risk of cancer was increased in patients with IBD in all age categories compared with non-IBD individuals (<50 years: adjusted hazard ratio [aHR], 1.59; 95% confidence interval [CI], 1.43-1.77; 50-65 years: aHR, 1.31; 95% CI, 1.19-1.44; and >65 years: aHR, 1.14; 95% CI, 1.05-1.24). Monotherapy (aHR, 1.36; 95% CI, 1.17-1.57) and combination therapy (aHR, 2.49; 95% CI, 1.64-3.78) were associated with an increased risk of cancer compared to unexposed patients with IBD. Among elderly patients (>65 years), the aHR was 2.79 (95% CI, 1.24-6.28) in those receiving combination therapy. In patients discontinuing thiopurines, aHRs returned to the level of unexposed (aHR, 0.89; 95% CI, 0.78-1.01). The aHR was positively associated with cumulative thiopurine exposure and in patients with >5 years of exposure, reaching an aHR of 1.36 (95% CI, 1.15-1.61). CONCLUSIONS: Thiopurines were associated with increased hazard of cancer, especially when used in combination therapy in the elderly. The hazard increased by 36% when patients were exposed to thiopurines for more than 5 years. Reassuringly, the hazard returned to baseline after discontinuation of thiopurines.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wewer MD, Letnar G, Andersen KK, et al. Thiopurines and the Risk of Cancer in Patients With Inflammatory Bowel Disease and Reference Individuals Without Inflammatory Bowel Disease: A Danish Nationwide Cohort Study (1996-2018). Clin Gastroenterol Hepatol. 2024. PMID: 39209201. doi:10.1016/j.cgh.2024.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。